132 related articles for article (PubMed ID: 17186240)
1. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Lindhagen E; Nissle S; Leoni L; Elliott G; Chao Q; Larsson R; Aleskog A
Cancer Chemother Pharmacol; 2007 Sep; 60(4):545-53. PubMed ID: 17186240
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
Lindhagen E; Rickardson L; Elliott G; Leoni L; Nygren P; Larsson R; Aleskog A
Invest New Drugs; 2007 Aug; 25(4):297-303. PubMed ID: 17440681
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Robak P; Linke A; Cebula B; Robak T; Smolewski P
Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
[TBL] [Abstract][Full Text] [Related]
4. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay.
Morabito F; Messina G; Oliva B; Ramirez F; Callea V; Brugiatelli M; Nobile F
Haematologica; 1993; 78(4):213-8. PubMed ID: 8294052
[TBL] [Abstract][Full Text] [Related]
5. SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.
Lentzsch S; Elliott G; Roodman GD
Arch Pharm (Weinheim); 2007 Oct; 340(10):511-6. PubMed ID: 17849446
[TBL] [Abstract][Full Text] [Related]
6. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Yasui H; Hideshima T; Ikeda H; Ocio EM; Kiziltepe T; Vallet S; Okawa Y; Neri P; Sukhdeo K; Podar K; Chauhan D; Richardson PG; Raje N; Carrasco DR; Anderson KC
Leukemia; 2007 Mar; 21(3):535-40. PubMed ID: 17268521
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance mechanisms in chronic lymphocytic leukemia.
Ribrag V; Massade L; Faussat AM; Dreyfus F; Bayle C; Gouyette A; Marie JP
Leukemia; 1996 Dec; 10(12):1944-9. PubMed ID: 8946935
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
11. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.
Thornton PD; Matutes E; Bosanquet AG; Lakhani AK; Grech H; Ropner JE; Joshi R; Mackie PH; Douglas ID; Bowcock SJ; Catovsky D
Ann Hematol; 2003 Dec; 82(12):759-65. PubMed ID: 14551737
[TBL] [Abstract][Full Text] [Related]
12. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
Gerrard G; Butters TD; Ganeshaguru K; Mehta AB
Eur J Pharmacol; 2009 May; 609(1-3):34-9. PubMed ID: 19285492
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple myeloma with SDX-308.
Feng R; Lentzsch S
Drug News Perspect; 2007 Sep; 20(7):431-5. PubMed ID: 17992265
[TBL] [Abstract][Full Text] [Related]
14. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
15. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.
Robak T; Blonski JZ; Kasznicki M; Góra-Tybor J; Dmoszyñska A; Skotñicki A
Haematologica; 2005 Jul; 90(7):994-6. PubMed ID: 15996945
[TBL] [Abstract][Full Text] [Related]
16. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
[TBL] [Abstract][Full Text] [Related]
19. [Present status of chemotherapy in ALL and CLL].
Ogawa M
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1882-7. PubMed ID: 6964032
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
